FOXO1 and metastatic neoplasm: Hibbitts et al. evaluated data from six COG trials to evaluate risk stratification with the addition of FOXO1 fusion status to traditional clinical features, and found that FOXO1 status (positive vs. negative) was a significant predictor of EFS and OS for patients with both localized (EFS 52% vs. 78%; OS 65% vs. 88%) and metastatic disease (EFS 6% vs. 46%; OS 19% vs. 58%) [88].